Human-in-the-Loop AI Use in Ongoing Process Verification in the Pharmaceutical Industry
Open Access
- 6 December 2025
- journal article
- review article
- Published by MDPI AG in Information
- Vol. 16 (12) , 1082
Abstract
The pharmaceutical industry’s pursuit of enhanced product quality, regulatory compliance, and operational efficiency has catalyzed the integration of Artificial Intelligence (AI) into Ongoing Process Verification (OPV) frameworks. This comprehensive review examines the synergistic application of Human-in-the-Loop (HITL) AI systems within OPV, contextualized by the evolving regulatory landscape, particularly the newly introduced Annex 22 of the European Union Good Manufacturing Practices (EU-GMP). The review delineates the sector’s strategic shift from traditional validation models toward dynamic, data-driven approaches that leverage AI for real-time monitoring, predictive analytics, and proactive process control. Central to this transformation is the HITL paradigm, which ensures that human expertise remains embedded in critical decision-making loops, thereby safeguarding patient safety, product quality, data integrity, and ethical responsibility. Annex 22 explicitly mandates deterministic behavior, traceability, and explainability for AI models used in GMP-critical applications, excluding adaptive and probabilistic systems from such contexts. The document also reinforces the necessity of multidisciplinary governance, rigorous validation protocols, and risk-based oversight throughout the AI lifecycle. This paper synthesizes current industry practices, regulatory expectations, and technological capabilities, offering a structured framework for compliant AI deployment in OPV. By aligning AI implementation with Annex 22 principles and existing GMP frameworks (e.g., Annex 11 and ICH Q9), the pharmaceutical sector can harness AI’s transformative potential while maintaining robust regulatory compliance. The review concludes with actionable recommendations for integrating HITL AI into OPV strategies, fostering a resilient, transparent, ethical, and future-ready manufacturing ecosystem.Keywords
Funding Information
- Departament de Recerca i Universitats, Generalitat de Catalunya (AGAUR 2021 SGR 01068)
- Universidad de Costa Rica (817-C5-253)
This publication has 17 references indexed in Scilit:
- Towards enterprise-wide pharma 4.0 adoptionScientific African, 2025
- Human-in-the-loop or AI-in-the-loop? Automate or Collaborate?Proceedings of the AAAI Conference on Artificial Intelligence, 2025
- Artificial Intelligence Empowering Process Analytical Technology and Continued Process Verification in BiotechnologyGEN Biotechnology, 2025
- Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-MakingThe AAPS Journal, 2025
- Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillanceEuropean Journal of Pharmaceutical Sciences, 2024
- Advanced methodologies for model-based optimization and control of pharmaceutical processesCurrent Opinion in Chemical Engineering, 2024
- Fairness of artificial intelligence in healthcare: review and recommendationsJapanese Journal of Radiology, 2023
- Human-in-the-loop machine learning: a state of the artArtificial Intelligence Review, 2022
- Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the futureInternational Journal of Pharmaceutics, 2021
- Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing PracticesDrug Safety, 2021